Skip to search boxSkip to navigationSkip to main content

Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia

Scholary Output:
Contribution to journal
Article
 Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

​​​​Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia Click to enlarge page​​.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
 Peer-review

Original language

English (US)

Article number

NU18041AH5C

Journal (Volume, Issue Number)

Journal of Clinical Psychiatry (Volume 81, Issue 1)

Publication milestones

  • Published - 01/2020

Publication status

Published - 01/2020

ISSN

0160-6689

Publication IDs

  • Scopus: 85078688845
  • PubMed: 31995674

Access to documents

Publication metrics

Metrics

Scopus
citations
3, opens in new tab
SciVal
Author count
2
SciVal
Paper percentile
49
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
3
Captures
13

Funding Details

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Marlene P. Freeman, MD, Editor in Chief, has received research funding from JayMac and Sage; has been a member of the advisory boards for Otsuka, Alkermes, and Sunovion; has been a member of the Independent Data Safety and Monitoring Committee for Janssen; has been a member of the Steering Committee for Educational Activities for Medscape; and, as a Massachusetts General Hospital (MGH) employee, works with the MGH National Pregnancy Registry, which is sponsored by Teva, Alkermes, Otsuka, Actavis, and Sunovion, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships. Faculty financial disclosure appears on the next page. the highlights of the teleconference series “Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia,” which was held in April, May, and June 2019. This report was prepared and independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and was supported by an educational grant from Neurocrine Biosciences, Inc.